[Table/Fig-4]:
Effect of ranolazine and trimetazidine on glycemic, hemodynamic parameters and QTc interval
| S. No | Parameters studied | Ranolazine 500 mg BD (N=23) | Trimetazidine 35 mg BD (N=24) | ||
|---|---|---|---|---|---|
| Before Mean ± SD | After 12 wks Mean ± SD | Before Mean ± SD | After 12 wks Mean ± SD | ||
| 1 | HbA1c (%) | 9.0 ± 1.6 | 8.7 ± 1.5 | 8.6 ± 1.5 | 8.6 ± 2.4 |
| 2 | FBG (mg/dl) | 163.9 ± 45.2 | 158.2 ± 41.6 | 153.6 ± 60.8 | 168.1 ± 68.1 |
| 3 | PBG (mg/dl) | 271.1 ± 78.4 | 295.3 ± 91.6 | 248.3 ± 78.7 | 259.7 ± 75.5 |
| 4 | †Angina attacks / wk | 1.7 ± 6.1 | 1.2 ± 1.7 | 2.0 ± 4.7 | 1.4 ± 2.2 |
| 5 | † Sublingual nitrate consumption / wk | 1.7 ± 3.1 | 2 ± 4.7 | 2.7 ± 8.1 | 1.4 ± 2.6 |
| 6 | †QT interval (ms) | 360.1 ± 29.5 | 367.1 ± 35.5 | 354.8 ± 29.4 | 362.6 ± 37.4 |
| 7 | QTc interval (ms) | 401.1 ± 43.2 | 408.2 ± 33.2 | 395 ± 40.3 | 399.4 ± 24.8 |
| 8 | Heart rate (bpm) | 76.5 ± 16.2 | 76.4 ± 16.7 | 75.5 ± 14.5 | 76.9 ± 11.9 |
| 9 | Systolic blood pressure (mmHg) | 128.5 ± 19.9 | 126.4 ± 19.7 | 131.7 ± 22.8 | 126.3± 20.9 |
| 10 | †Diastolic blood pressure (mmHg) | 80.5 ± 14.2 | 81.4 ± 9.9 | 81.3 ± 12.1 | 79.4 ± 13.4 |
HbA1c- glycated haemoglobin, FBG – fasting blood glucose, PBG – post prandial blood glucose, Values are expressed as mean±SD (Standard deviation); † Wilcoxon matched-pairs signed-ranks test (Non parametric test used as Kolmogorov and Smirnov normality was not passed)